Camrelizumab Combined With Cisplatin in the Treatment of Advanced Cutaneous Squamous Cell Carcinoma

Sponsor
Henan Cancer Hospital
Study ID
NCT05490485
Phase
PHASE2
Status
Unknown

Conditions

  • Squamous Cell Carcinoma of the Skin

Eligibility Criteria

Sex
ALL
Age
18 Years - 99 Years
Healthy Volunteers
Not accepted

Interventions

  • Camrelizumab — DRUG
    Camrelizumab combined with cisplatin for advanced cutaneous squamous cell carcinoma

Study Details

This study is a card Rayleigh bead single combined cisplatin treatment of advanced squamous cell carcinoma of the skin resistance of single arm phase II study, open, single center, plan in two years into the group of 20 cases with histologic diagnosis of lymph node metastasis or distant metastasis CSCC of (1) or surgery can't/couldn't thorough radiotherapy, CSCC of locally advanced (class 2), To evaluate the efficacy of camrelizumab (PD-1 mab) combined with cisplatin in the treatment of advanced CSCC.

Key Dates

Start date
Aug 5, 2022
Status verified
Aug 2023
Primary completion
Jul 31, 2024
Completion
Jul 31, 2024

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Camrelizumab
    Camrelizumab (PD-1 MAB) combined with cisplatin for advanced cutaneous squamous cell carcinoma

Primary Outcome Measure

Progression-free survival [ Time Frame: Up to approximately 24months ]

Related Studies